Intellia Therapeutics Gains FDA Priority Review for Lonvo-z in HAE
CAMBRIDGE, Mass. — September 8, 2026 Intellia Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted...
hereditary angioedema
Advertisement
Pharvaris Reports Positive Phase 3 CHAPTER-3 Data for Deucrictibant XR
ZUG, Switzerland — September 8, 2026 Pharvaris announced positive topline results from the CHAPTER-3 pivotal Phase 3 study evaluating...
Apollo Therapeutics Reports Positive APL-10456 Phase 1 Data
BOSTON, U.S. & CAMBRIDGE, U.K. — August 25, 2026 Apollo Therapeutics announced positive immunogenicity and cross-species activity data from...
BioCryst Wins Japan Approval for Pediatric ORLADEYO
TOKYO, Japan — August 25, 2026 BioCryst Pharmaceuticals announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has...
Pharvaris Advances Oral HAE Therapy with FDA NDA Acceptance
ZUG, Switzerland, July 6, 2026 Pharvaris announced that the U.S. Food and Drug Administration (FDA) has accepted the New...
Advertisements
Argo Biopharma Reports Positive Phase 2 HAE Data for BW-20805
SHANGHAI, China & NEW YORK, USA – June 8, 2026 Argo Biopharma has announced positive updated Phase 2 results...
BioCryst, Neopharmed Sign $345M Europe HAE Deal
RESEARCH TRIANGLE PARK, NORTH CAROLINA, May 04, 2026 BioCryst Pharmaceuticals has announced a strategic European licensing agreement with an...
Intellia Nears Phase 3 CRISPR Data in HAE Breakthrough
Cambridge, Massachusetts | April 24, 2026 Intellia Therapeutics has announced a pivotal milestone in genetic medicine, confirming that it...
KalVista Showcases EKTERLY Data at AAAAI 2026 Meet
FRAMINGHAM, Mass. & SALISBURY, England, Feb. 12, 2026 — KalVista Pharmaceuticals announced the presentation of new clinical and real-world...
WINREVAIR Achieves Phase 2 Success in CpcPH Due to HFpEF
RAHWAY, N.J., Nov. 18, 2025 — Merck (NYSE: MRK) announced positive topline results from the Phase 2 CADENCE study,...
Advertisement
